June 22, 2020
Kyowa Kirin and Ultragenyx Pharmaceutical said on June 19 that their anti-FGF23 monoclonal IgG1 antibody Crysvita (burosumab) has been approved in the US for an additional indication of tumor-induced osteomalacia (TIO). Crysvita has earned the approval for the treatment of...read more